PATENT CLAIM ANALYSIS

Application Number: 16120170
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-01
Patent Classification: ["544", "324000"]

Abstract:
A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.

Claim (Index 50):
The method as claimed in  claim 32 , wherein the condition is selected from rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerous colitis, multiple sclerosis, lymphoproliferative diseases, rejection after organ transplantation, Wegener' granulomatosus, psoriasis, Mb Bechterews, Behcets disease, Guillain Barre, dermatomyositis, myositis, polymyositis, primary biliary cirrhosis, anti-phospholipid syndrome, autoimmune hepatitis, autoimmune cardiomyopathy, alopecia areata, atherosclerosis, type 1 diabetes, autoimmune uveitis, Goodpasteure's syndrome, Graves' disease, Hashimotos disease, mixed connective tissue disease, myasthenia gravis, pemphigus vulgaris, pernicious anemia, Sj\u00f6gren's syndrome, giant cell arteritis, ulcerative colitis, vasculitis, Churg-Strauss syndrome, postpolio syndrome, idiopathic thrombocytopenic purpura, Peyronie disease and Dupuytren's contracture.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 96.0
- Lexical Diversity: 1.08
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15447818', '14647400', '15899061', '15315461', '15315478']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8207800016883797
- 35 USC 102 Novelty (BERT): 0.5747406716913717
- Combined Prediction Score: 0.796176068688679
- Mean Citation Score: 477.80761600000005
- Max Citation Score: 496.26343
- Similarity Product: 371.9749268097012

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test